179170-56-0

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 173173-54-1 2-(2-phenyloxazol-4-yl)-ethanol 
• 201660-21-1 2-(2-phenyl-4-oxazolyl)ethyl methanesulfonate 
• 55-21-0 benzamide 
• 22086-89-1 (2-phenyloxazol-4-yl)acetic acid 
• 425381-67-5 methyl (2-phenyloxazol-4-yl)acetate 

Downstream Products

• 179170-38-8 4-[2-(2-Phenyl-4-oxazolyl)-ethoxy]phenylmethanol 
• 201660-23-3 O-[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenylmethyl]-N-triphenylmetyl-L-serine methyl ester 
• 201660-24-4 N-benzyloxycarbonyl-O-[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenylmethyl]-L-serine methyl ester 
• 201660-22-2 4-[2-[4-(bromomethyl)phenoxy]ethyl]-2-phenyloxazole 

Relevant academic research and scientific papers

HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING LIPID ACCUMULATION CONTAINING SAME

The present invention relates to a novel heterocyclic carboxylic acid derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for inhibiting the accumulation of lipids in the body.

Synthesis of 2-phenyloxazole derivatives containing amino acids as insulin sensitivity enhancers for treatment of type II diabetes

The search for Insulin Sensitivity Enhancers (ISE) for use in the treatment of Non-Insulin Dependent Diabetes Mellitus (NIDDM) has led to the preparation of N-[(phenylmethoxy)carbonyl]-O-[[4-[2-(2-phenyl-4-oxazolyl)-ethoxy]phenyl] methyl]-L-serine (1) and 7-[2-(2-phenyl-4-oxazolyl)ethoxyl]-L-1,2,3,4-tetrahydro-N-Cbz- isoquinoline-3-carboxylic acid (2), that contain a 2-phenyloxazole moiety linked to an amino acid in place of the 2,4-thiazolidinedione pharmacophore. The 2-phenyloxazole was incorporated into 1 and 2 in high yield by alkylation of 4-hydroxybenzaldehyde or methyl 7-1,2,3,4-tetrahydro-N-benzyloxycarbonyl-hydroxyisoquinoline-3-carboxylate with 2-(2-phenyl-4-oxazolyl)ethyl p-toluenesulfonate (16). Successful incorporation of serine into 1 required use of an N-trityl protecting group to minimize β-elimination and epimerization at the α-center.

Hypoglycemic and hypolipidemic compounds

This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.

Oral hypoglycemic agents

Antihyperglycemic compounds selected from the group consisting of C-substituted pentacycloazoles and N-alkyl-substituted pentacycloazoles.

Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5- lipoxygenase

Azole phenoxy hydroxyureas are a new class of 5-lipoxygenase (5-LO) inhibitors. Structure-activity relationship studies have demonstrated that electronegative substituents on the 2-phenyl portion of the oxazole tail increased the ex vivo potency of these